WAVE Life Sciences Ltd. (NASDAQ:WVE) is expected to report second quarter earnings results, before market open, on Monday 10th August 2020.
Analysts polled by Thomson Reuters anticipate second quarter loss of $ 0.97 per share.
Looking ahead, the full year loss are expected at $ 3.6 per share on the revenues of $ 38.83 million.
Previous Quarter Performance
WAVE Life Sciences Ltd. communicated loss for the first quarter of $ 1.38 per share, from the revenue of $ 4.16 million. The quarterly revenues compared with the same quarter last year. The consensus estimates are loss of $ 1.20 per share from $ 6.05 million in revenue. The bottom line results missed street analysts by $ 0.18 or 15 percent, at the same time, top line results fell short of analysts by $ 1.89 million or 31.24 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of WAVE Life Sciences Ltd.
Stock Performance
According to the previous trading day, closing price of WVE was $ 9.15, representing a 38.43 % increase from the 52 week low of $ 6.61 and a 77.11 % decrease over the 52 week high of $ 39.98.
The company has a market capital of $ 326.95 million and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”WVE” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
WAVE Life Sciences Ltd. will be hosting a conference call at 8:30 AM eastern time on 10th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.wavelifesciences.com
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It focuses on proprietary programs in neurology in the central nervous system and neuromuscular system.
